Ruxolitinib (free base)

Antineoplastic, anti-inflammatory and immunomodulating agent. Orally bioavailable potent ATP mimetic that inhibits both JAK1 and JAK2 with IC50 values of 2.7 and 4.5nM, respectively and is less selective for JAK3 (IC50=322nM). Affects DC differentiation and function, leading to impaired T cell activation. Used in the treatment of myeloproliferative neoplasms and psoriasis. Anticancer agent. Shown to induce apoptosis and autophagy. Potent and selective inhibitor of HIV-1 replication and virus reactivation in vitro. It is investigated against the spread of the SARS-CoV-2 (COVID-19).

Specyfikacja/Zawartość:

• Predicted Molecular Weight: 306,4
• Physical State: Lyophilized
• Purity: greater than or equal to 98% (HPLC)
• Formula: C17H18N6
• Source: N/A
• CAS: 941678-49-5
• Soluble in: Soluble in DMSO (>100mg/ml) and water (8mg/ml). Slightly soluble in 100% ethanol.
• InChi Key: HFNKQEVNSGCOJV-OAHLLOKOSA-N
• Smiles: N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=NC=NC2=C1C=CN2
• RTECS: N/A
• Identity: Determined by 1H-NMR and MS.
• Merk: N/A

Wysyłka i przechowywanie:

Short Term Storage: +4C. Long Term Storage: -20C. Handling Advice: Keep cool and dry. Use/Stability: Stable for at least 2 years after receipt when stored at -20C.

Inne:

For Research Use Only